

References

I-123

1. Cristofnili M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* 2016;425–39.
2. Musolino A, Campone M, Neven P et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2– breast cancer that had progressed during or after prior endocrine therapy. *Breast Cancer Research.* 2017;19-18.
3. Faslodex® (Fulvestrant) for injection [package insert]. AstraZeneca Pharmaceuticals LP. Wilmington, DE. Revised 08/2020.
4. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. *Journal of Clinical Oncology.* 2017;35(25):2875-2887.
5. Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im S, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. *The Oncologist.* 2017;22:1028-1038.
6. Xu L, Yan N, Li Z, et al. A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis. *OncoTargets & Therapy.* 2018;11:8389-8398.
7. Quenel-Tueux N, Debled M, Rudewicz J, et al. Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. *British Journal of Cancer.* 2015;113(4):585-594.
8. Zhang T, Feng F, Zhao W, et al. Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: A network meta-analysis. *Cancer Management & Research.* 2018;10:5869-5880.
9. Sledge GW Jr, Toi M, Neven P, et. al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. *JAMA Oncol.* 2020;6(1):116-124.

10. Robertson JFR, Jiang Z, Di Leo A, et al. A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. *Breast cancer (Tokyo, Japan)*. 2019;26(6):703-711.
11. Li M, Xiong Y, Liao C, et al. Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials. *Breast cancer research and treatment*. 2020;180(2):269-278.
12. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Fulvestrant.
13. [Fulvestrant] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 02/09/2021.
14. National Comprehensive Cancer Network (NCCN). Fulvestrant. NCCN Drugs and Biologics Compendium®. 2021.
15. Micromedex DrugDex Compendium®. 2021. Fulvestrant (Faslodex).